SINGAPORE, Dec. 9, 2025 /PRNewswire/ -- Immortal Dragons, the $40 million longevity-focused innovation fund, today announced its strategic investment in Etheros, a research-driven technology company developing proprietary water-soluble fullerene-based catalytic antioxidant materials....
Hence then, the article about immortal dragons backs etheros pharmaceuticals targeting aging related disease with breakthrough catalytic antioxidants was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Immortal Dragons Backs Etheros Pharmaceuticals: Targeting Aging-Related Disease with Breakthrough Catalytic Antioxidants )
Also on site :
- Dispatch centers in Marin County down, service outage reported for 911 calls
- Hawaiian Airlines announces Kahu'ewai Hawai'i Investment Plan of more than $600M over five years to modernize infrastructure and guest experience, and deepen its commitment to the community and sustainability
- Flutterwave buys Nigeria’s Mono in rare African fintech exit